Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Sponsor: Kadmon Corporation, LLC
Terminated
Sponsor opened Phase 2 Study.
Other terminated trials from Kadmon Corporation, LLC
- HER-2 Positive Breast Cancer · Phase PHASE1/PHASE2 · Sep 2015
- Carcinoma, Non-Small-Cell Lung · Phase PHASE3 · Jul 2013
- Hepatitis C · Phase PHASE4 · Oct 2007
More terminations from Kadmon Corporation, LLC
Other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with similar outcome
Browse all Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials
A PHASE2 clinical study on Autosomal Dominant Polycystic Kidney Disease (ADPKD), this trial is terminated or withdrawn. The trial is conducted by Kadmon Corporation, LLC and has accumulated 11 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
May 2022 — Jun 2022 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Apr 2022 — May 2022 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kadmon Corporation, LLC
For direct contact, visit the study record on ClinicalTrials.gov .